95635-56-6

Basic information

• Product Name: Ranolazine dihydrochloride
• Synonyms: (+/-)-4-[2-HYDROXY-3-(O-METHOXYPHENOXY)PROPYL]-1-PIPERAZINEACETO-2',6'-XYLIDIDE DIHYDROCHLORIDE;n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide dihydrochloride;(+/-)-N-(2,6-DIMETHYLPHENYL)-4-[2-HYDROXY-3-(2-METHOXYPHENOXY)PROPYL]-1-PIPERAZINEACETAMIDE DIHYDROCHLORIDE;RANOLAZINE DIHYDROCHLORIDE;RANOLAZINE HCL;Ranolazine DiHCI;Ranolazine and salt;(±)-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide
• CAS NO: 95635-56-6
• Molecular Formula: C24H35Cl2N3O4
• Molecular Weight: 500.46
• Product Categories: Active Pharmaceutical Ingredients;Aromatics Compounds;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Ranolazine;Cardiovascular APIs
• Mol File: 95635-56-6.mol
• Article Data: 0

Chemical Properties

• Melting Point: 222-229.5 °C(lit.)
• Boiling Point: 624.1 °C at 760 mmHg
• Flash Point: 331.2 °C
• Appearance: off-white/solid
• Vapor Pressure: 1.94E-16mmHg at 25°C
• Storage Temp.: Desiccate at RT
• Solubility: H2O: 10 mg/mL, soluble
• Stability: Hygroscopic
• Merck: 14,8111
• CAS DataBase Reference: Ranolazine dihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Ranolazine dihydrochloride(95635-56-6)
• EPA Substance Registry System: Ranolazine dihydrochloride(95635-56-6)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• RTECS: TK7845370
• Hazardous Substances Data: 95635-56-6(Hazardous Substances Data)

Usage

Description

Ranolazine is a piperazine derivative with cardioprotective activity. It reduces the late sodium current (INa) in mouse myocytes expressing the long QT syndrome 3 mutant sodium channel DKPQ, ventricular myocytes isolated from a canine model of heart failure, guinea pig ventricular myocytes exposed to hydrogen peroxide or anemone toxin-II, and HEK293 cells expressing human Nav1.5 channels (IC50s = 5.9-15 μM) as well as the late potassium current (IKr) in canine ventricular myocytes and HEK293 cells (IC50s = 11.5 and 14.4 μM, respectively). Ranolazine also inhibits radioligand binding to α1-, β1-, and β2-adrenergic receptors (Kis = 8.2-19.5, 1.4-8.6, and 0.5-14.8 μM, respectively). In vivo, ranolazine (480 μg/kg per min) reduces clofilium-induced prolongation of the QTc interval and Torsade de Pointes (TdP) in rabbits. Ranolazine also reduces interstitial collagen deposition as well as atrial natriuretic peptide (ANP; Item Nos. 24539 | 24276), connective tissue growth factor (CTGF), brain natriuretic peptide (BNP; ), and matrix metalloproteinase-2 (MMP-2) mRNA levels, and prevents left ventricular dilation in a mouse model of cardiotoxicity induced by doxorubicin .

Chemical Properties

White Crystalline Powder

Uses

Different sources of media describe the Uses of 95635-56-6 differently. You can refer to the following data:
1. treatment of angina and congestive heart failure
2. Ranolazine Dihydrochloride is an anti-ischemic agent which modulates myocardial metabolism. Antianginal.
3. Anti-ischemic agent which modulates myocardial metabolism. Antianginal

Biological Activity

Antianginal agent with antiarrhythmic properties that acts as a partial fatty acid oxidation inhibitor. Activates pyruvate dehydrogenase in ischemic myocytes to promote glucose oxidation, switching substrate utilization from fatty acids to glucose. Also shown to inhibit late I Na and I Kr currents.

Biochem/physiol Actions

Ranolazine is a derivative of anti-ischemic piperazine and acts as sodium (Na+)-current inhibitor. It has the potential to treat diastolic heart failure and helps in ameliorating myocardial diastolic function.

InChI:InChI=1/C24H33N3O4.2ClH/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3;;/h4-10,20,28H,11-17H2,1-3H3,(H,25,29);2*1H